RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Celldex Therapeutics Stock

Celldex Therapeutics ROE 2024

Celldex Therapeutics ROE

-0.33

Ticker

CLDX

ISIN

US15117B2025

WKN

A2PEAB

In 2024, Celldex Therapeutics's return on equity (ROE) was -0.33, a -4.3% increase from the -0.34 ROE in the previous year.

Celldex Therapeutics Aktienanalyse

What does Celldex Therapeutics do?

Celldex Therapeutics is an American company specializing in the development and research of therapeutics for diseases of the immune system and cancer. The company was founded in 2004 and is headquartered in Hampton, New Jersey. Celldex Therapeutics was originally established as a subsidiary of Alteon Inc., which focused on developing drugs for heart diseases. In 2004, the company became independent. Celldex Therapeutics has continuously invested in the development of new medicines for various areas of oncology. Its business model is based on the development and marketing of innovative therapeutics. The company collaborates closely with leading research institutions in the field of immunology and oncology to develop new therapies. Celldex Therapeutics also has partnerships with major pharmaceutical companies such as Pfizer, Roche, and Bristol-Myers Squibb. The company is divided into different divisions, including the development of vaccines and immunotherapies for various types of cancer, as well as the development of protein therapeutics for the treatment of inflammatory diseases and other immune system disorders. Celldex Therapeutics has already launched several products or is currently developing them, including CDX-1127, a immunomodulatory antibody for cancer treatment; CDX-1135, a novel vaccine against the Epstein-Barr virus; CDX-1401, an immunotherapy for various types of cancer based on dendritic cells; and Glembatumumab vedotin, an antibody-drug conjugate for the treatment of different types of cancer. In summary, Celldex Therapeutics is a biotech company specialized in innovative therapies for cancer and immune system diseases. The company collaborates with research institutions and pharmaceutical companies to bring its products to patients. Its wide portfolio and expertise contribute to improving patient care. Celldex Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Celldex Therapeutics's Return on Equity (ROE)

Celldex Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Celldex Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Celldex Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Celldex Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Celldex Therapeutics stock

What is the ROE (Return on Equity) of Celldex Therapeutics this year?

The ROE of Celldex Therapeutics this year is -0.33 undefined.

How has the Return on Equity (ROE) of Celldex Therapeutics developed compared to the previous year?

The ROE of Celldex Therapeutics has increased by -4.3% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Celldex Therapeutics?

A high ROE indicates that Celldex Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Celldex Therapeutics?

A low ROE can indicate that Celldex Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Celldex Therapeutics affect the company?

A change in ROE (Return on Equity) of Celldex Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Celldex Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Celldex Therapeutics?

Some factors that can influence Celldex Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Celldex Therapeutics pay?

Over the past 12 months, Celldex Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Celldex Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Celldex Therapeutics?

The current dividend yield of Celldex Therapeutics is .

When does Celldex Therapeutics pay dividends?

Celldex Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Celldex Therapeutics?

Celldex Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Celldex Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Celldex Therapeutics located?

Celldex Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Celldex Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Celldex Therapeutics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Celldex Therapeutics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Celldex Therapeutics in the year 2023?

In the year 2023, Celldex Therapeutics distributed 0 USD as dividends.

In which currency does Celldex Therapeutics pay out the dividend?

The dividends of Celldex Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Celldex Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Celldex Therapeutics

Our stock analysis for Celldex Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celldex Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.